A11 competitively binds PD-L1, inhibiting USP7-mediated deubiquitination, which leads to increased PD-L1 degradation and improved CD8+ T cell–mediated tumor cell killing, resulting in synergistic antitumor effects when combined with PD-1 blockade [131]. This evidence concerns the gene CD8A and neoplasm.